Callan JMB Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: revenue base $5.72M (FY2025, down from $13.2M in FY2023 due to customer concentration losses) growing 8%/yr for years 1-5 then 4%/yr for years 6-10; FCF margin ramps from -3% in year 1 to 8% by year 10 as the business stabilizes and diversifies into GLP-1/compounding-pharmacy cold-chain logistics; 14% discount rate; 2.5% terminal growth; PV of 10-yr FCF ~$1.7M plus PV of terminal value ~$2.0M = EV ~$3.7M; less net debt ~$1.3M ($2.13M cash less $3.45M total liabilities at FY2025 year-end); equity value ~$2.4M; 5.75M shares outstanding.

Reasoning: Callan JMB's revenue has fallen by more than half since 2023 on customer concentration losses and its FCF is currently negative, so the DCF uses a recovery-and-stabilization path anchored to its actual SEC-reported revenue decline and 2024-2025 losses rather than assuming a turnaround no analyst has modeled; the 14% discount rate reflects its micro-cap size, thin liquidity, and weak current cash position.